Hill-Rom (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, January 9th.
According to Zacks, “Hill-Rom has been witnessing an increase in revenues on strong international growth. The company is currently focused on gaining traction in the untapped international market on successful execution of its strategy, courtesy its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted and operating margin buoys optimism. Overall, Hill-Rom has outperformed the broader industry in the past six months. On the flip side, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.”
Other equities research analysts have also issued reports about the stock. ValuEngine upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating in a report on Thursday, November 16th. Stifel Nicolaus reiterated a “buy” rating and issued a $92.00 target price on shares of Hill-Rom in a report on Wednesday, November 29th. Needham & Company LLC lowered their price objective on shares of Hill-Rom from $93.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, November 6th. KeyCorp reissued a “buy” rating and set a $89.00 price objective (up previously from $82.00) on shares of Hill-Rom in a research report on Sunday, November 5th. Finally, Morgan Stanley downgraded shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Hill-Rom has a consensus rating of “Hold” and a consensus target price of $94.88.
Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. equities research analysts anticipate that Hill-Rom will post 4.32 earnings per share for the current fiscal year.
In other news, SVP Paul Sherwood Johnson sold 1,000 shares of Hill-Rom stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total value of $82,990.00. Following the completion of the transaction, the senior vice president now owns 1,066 shares of the company’s stock, valued at approximately $88,467.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John J. Greisch sold 125,241 shares of Hill-Rom stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the transaction, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The disclosure for this sale can be found here. In the last three months, insiders sold 226,241 shares of company stock valued at $18,708,644. Insiders own 2.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of HRC. Legal & General Group Plc lifted its stake in shares of Hill-Rom by 24.8% during the 2nd quarter. Legal & General Group Plc now owns 53,284 shares of the medical technology company’s stock worth $4,242,000 after buying an additional 10,596 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hill-Rom by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after buying an additional 204 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Hill-Rom by 5.5% during the 2nd quarter. Principal Financial Group Inc. now owns 261,102 shares of the medical technology company’s stock worth $20,786,000 after buying an additional 13,509 shares during the last quarter. Swiss National Bank lifted its stake in shares of Hill-Rom by 1.0% during the 2nd quarter. Swiss National Bank now owns 109,400 shares of the medical technology company’s stock worth $8,709,000 after buying an additional 1,100 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Hill-Rom by 0.5% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,734 shares of the medical technology company’s stock worth $695,000 after buying an additional 46 shares during the last quarter. Institutional investors own 81.92% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Hill-Rom (HRC) Downgraded by Zacks Investment Research” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/hill-rom-hrc-cut-to-hold-at-zacks-investment-research/1820971.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.